Tobira Therapeutics (TBRA) Reports Q2 Loss Per Share of $0.99

Tobira Therapeutics (NASDAQ: TBRA) reported Q2 EPS of ($0.99), versus ($19.62) reported last year. Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Tobira Therapeutics (TBRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c